Search

Displaying results 2791 - 2800 of 10000 in total
  1. Drug

    Remikiren

    go.drugbank.com/drugs/DB00212
    Experimental

    Remikiren is an orally active, high specificity renin inhibitor.

  2. Drug

    Opicapone

    go.drugbank.com/drugs/DB11632
    ApprovedInvestigational

    Opicapone is a potent, reversible, and peripherally-acting third-generation inhibitor of catechol-o-methyltransferase (COMT), an enzyme involved in the breakdown of various catecholamines including dopamine … Exhibiting a long duration of action that exceeds 24 hours, opicapone can be administered once-daily [L2336] and demonstrates the lowest risk for cytotoxicity compared to other catechol-O-methyltransferase

  3. Drug

    Carbetocin

    go.drugbank.com/drugs/DB01282
    ApprovedInvestigational

    It is an analogue of oxytocin, and its action is similar to that of oxytocin -- it causes contraction of the uterus. … Carbetocin is a drug used to control postpartum hemorrhage, bleeding after giving birth.

    Products: ENJEKSİYONLUK ÇÖZELTİ, 1 ADET, ENJEKSİYONLUK ÇÖZELTİ, 5 ADET
  4. Drug

    Eplontersen

    go.drugbank.com/drugs/DB16199
    ApprovedInvestigational

    [A262985] As eplontersen targets both the WT and mutant TTR, it poses tremendous promises as a treatment. … It was previously investigated as a potential treatment for hereditary transthyretin-mediated amyloidosis.

  5. Drug

    Metergoline

    go.drugbank.com/drugs/DB13520
    Approved

    Metergoline is an ergot-derived psychoactive drug that acts as a ligand for serotonin and dopamine receptors. … Metergoline is an antagonist at various 5-HT receptor subtypes at a relatively low concentration and agonist at dopamine receptors.

  6. Drug

    Zidesamtinib

    go.drugbank.com/drugs/DB21623
    ApprovedInvestigational

    another ROS1 inhibitor has failed rather than as an alternative first choice. … Zidesamtinib is an orally administered ROS1 kinase inhibitor designed to remain active against ROS1 resistance mutations.

  7. Drug

    Pozelimab

    go.drugbank.com/drugs/DB15218
    ApprovedInvestigational

    CD55-deficient protein-losing enteropathy (PLE), or CHAPLE disease, is an ultra-rare hereditary disease, with fewer than 100 patients diagnosed worldwide or fewer than 10 patients in the US. … [A261115] The loss of CD55 can therefore induce complement hyperactivation, causing the unwanted formation of membrane-attacking complex and resulting in paroxysmal nocturnal hemoglobinuria and complement-mediated

  8. Drug

    Seproxetine

    go.drugbank.com/drugs/DB06731
    Experimental

    Seproxetine is also known as (S)-norfluoxetine. It is a selective serotonin reuptake inhibitor (SSRI). It is an active metabolite of fluoxetine. … Seproxetine was being investigated by Eli Lilly as an antidepressant but development was never completed and the drug was never marketed.

  9. Drug

    Chlormerodrin Hg-197

    go.drugbank.com/drugs/DB09406
    Approved

    Chlormerodrin Hg-197 is a radiolabelled form of chlormerodrin, an organomercury compound that was previously used as a diuretic. Its radiolabelled form was used as diagnostics in brain scans.

  10. Drug

    Efavirenz

    go.drugbank.com/drugs/DB00625
    ApprovedInvestigational

    Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with … Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human

    Categories: Inducers of Drug Clearance, Metabolic Side Effects of Drugs and SubstancesProducts: STOCRIN 600 MG FILM TABLET, 30 ADET